Recent events
Recent events tied to this brand in public sources.
Back to profile4 entries
2019
Roche completes acquisition of Spark Therapeutics
Roche completed its acquisition of Spark Therapeutics after Spark accepted a tender offer for all outstanding common shares at $114.50 per share. Spark became a wholly owned subsidiary of Roche, and its shares would no longer be traded on Nasdaq.
2019
Regulators close investigation into Roche's acquisition of Spark Therapeutics
The U.S. Federal Trade Commission and the U.K. Competition and Markets Authority closed their 10-month investigation into Roche's acquisition of Spark Therapeutics and whether it would harm competition in the hemophilia A treatment space.
2019
UK regulator clears Roche's acquisition of Spark Therapeutics
The UK Competition and Markets Authority cleared Roche's $4.3 billion acquisition of Spark Therapeutics. The deal still required US regulatory approval.
2019
Regulators approve Roche-Spark acquisition
The U.K. Competition and Markets Authority and the U.S. Federal Trade Commission approved the Roche-Spark acquisition on Monday, clearing the remaining regulatory hurdles described in the report.